JERUSALEM, July 30 (Reuters) - Teva Pharmaceutical

Industries reported a higher than expected rise in

second-quarter profit, helped by strong sales gains of its

branded drugs to treat migraines, Huntington's disease and

schizophrenia.

The world's largest generic drugmaker said on

Wednesday it earned 66 cents per diluted share, excluding

one-time items, in the April-June quarter, up from 61 cents a

share a year earlier. Revenue was flat in dollar terms at $4.18

billion.

Analysts had forecast earnings of 62 cents per share

ex-items for the Israel-based company on revenue of $4.28

billion, LSEG I/B/E/S data showed.

Teva largely reaffirmed its 2025 estimates but revised its

adjusted EPS forecast to $2.50-$2.65 from $2.45-$2.65.